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Epstein Barr virus (EBV) infection is commonly associated with human cancer and, in
particular, with lymphoid malignancies. Although the precise role of the virus in the
pathogenesis of different lymphomas is largely unknown, it is well recognized that
the expression of viral latent proteins and miRNA can contribute to its pathogenetic
role. In this study, we compared the gene and miRNA expression profile of two
EBV-associated aggressive B non-Hodgkin lymphomas known to be characterized by
differential expression of the viral latent proteins aiming to dissect the possible
different contribution of such proteins and EBV-encoded miRNAs. By applying extensive
bioinformatic inferring and an experimental model, we found that EBV+ Burkitt lymphoma
presented with significant over-expression of EBV-encoded miRNAs that were likely to
contribute to its global molecular profile. On the other hand, EBV+ post-transplant diffuse
large B-cell lymphomas presented a significant enrichment in genes regulated by the
viral latent proteins. Based on these different viral and cellular gene expression patterns,
a clear distinction between EBV+ Burkitt lymphoma and post-transplant diffuse large
B-cell lymphomas was made. In this regard, the different viral and cellular expression
patterns seemed to depend on each other, at least partially, and the latency type most
probably played a significant role in their regulation. In conclusion, our data indicate that
EBV influence over B-cell malignant clones may act through different mechanisms of
transcriptional regulation and suggest that potentially different pathogenetic mechanisms
may depend upon the conditions of the interaction between EBV and the host that finally
determine the latency pattern.
Keywords: Epstein Barr Virus, latency, Burkitt lymphoma, post-transplant lymphoproliferative disorder, MicroRNA,
gene expression profiling
INTRODUCTION
Epstein Barr Virus (EBV) is a human gamma-herpesvirus that
normally infects 90–95% of the human normal population, and
persists for life of its host. This virus was first discovered in
endemic Burkitt Lymphoma (eBL), and was nominated as the
first human tumor virus. Today, a couple of human malignan-
cies, other than eBL, are known to harbor the virus, including
Post-Transplant Lymphoproliferative Disorder (PTLD) (Leoncini
et al., 1993; Bellan et al., 2003; Ghigna et al., 2013).
The manifestation of EBV infection is not the same in all EBV-
related tumors, since the virus can adopt different gene expression
programs for persistence, called latency types. There are three
major types of latencies in EBV-related tumors, which are defined
on the basis of the number of EBV latent proteins expressed, with
latency type III having the most extensive, where 5 EBV EBNAs
(EBV-Nuclear Antigen −1, −2, −3A, −3B, −3C, and -LP) and
3 LMPs (Latent Membrane Proteins −1, −2A, and −2B) are
expressed, followed by the less extensive form, i.e., latency type II,
where EBNA-1, LMP-1 and LMP-2s are expressed. In latency type
I, which is the most limited expression pattern, EBNA-1 molecule
is the only latent protein expressed (Gross, 2001; Piccaluga et al.,
2011; Onnis et al., 2012).
Furthermore, EBV encodes several non-coding RNA
molecules, which include Epstein-Barr virus (EBV)-encoded
small RNAs (EBERs) and two different families of microRNAs
(miRNAs), non-coding small RNAs with post-transcriptional
www.frontiersin.org December 2014 | Volume 5 | Article 728 | 1
Navari et al. EBV-encoded miRNA and genes in NHL
gene expression regulation ability: BART (BamHI A rightward
transcript) and BHRF1 (Bam HI fragment H rightward open
reading frame 1). EBERs, similarly to EBNA-1, are expressed in
all EBV latency types; the expression of BHRF-1 miRNAs seems
to be specific of latency type III while the expression of BART
miRNAs is common to all the latency types examined (Pratt
et al., 2009; Qiu et al., 2011; Yang et al., 2013; Vereide et al.,
2014).
Indeed, the different latency patterns regulate different tran-
scriptional programs as recently shown by Kelly et al. (2013).
Infection of human B cells by EBV in vitro results in their con-
stitutive proliferation and immortalization. The resulting cells,
called lymphoblastoid cell lines (LCLs), display type III of EBV
latency. Although the process of immortalization is not well
understood, recent studies focused on the epigenome of differ-
ent types of human B cells have indicated fundamental differences
between LCLs and other type of B-cell, e.g., activated B-cells
and BL-cells. (Kreck et al., 2013; Hansen et al., 2014; Hernando
et al., 2014) B-cell transformation associated with type III of
EBV latency is unlikely to occur in healthy individuals in vivo
owing to the immunogenic properties of EBNA-2 and -3 proteins
which would prompt EBV-infected cell elimination. However,
in severely immunocompromised individuals, e.g., organ trans-
plantation, malignant cells similar to LCLs are observed. These
malignancies, classified as PTLDs, most commonly are of dif-
fuse large B-cell lymphoma (DLBCL) histotype (Xia et al., 2008;
Morscio et al., 2013a,b). A high percentage (70–80%) of PTLDs
show positivity for EBV, and the role of the virus seems to be sub-
stantial since suppression of the immune system, especially of the
cytotoxic T cell branch, leads to higher titers of the virus in the
blood, and restoration of the immune response helps the patients
to eliminate the tumor (Savoldo et al., 2006). By means of the set
of its latent proteins, which are known to be able to deregulate an
extensive array of human genes, EBV can contribute to the devel-
opment of PTLD clones by interfering with different physiologic
processes, like proliferation, apoptosis and immune surveillance
(reviewed in Morscio et al., 2013b).
Burkitt Lymphoma is subdivided into three subtypes,
which consist of the endemic (eBL), sporadic (sBL), and
immunodeficiency-related (sometimes called HIV-BL) form.
While the majority (90%) of eBLs shows positivity for EBV,
the rate of EBV infection in the other two subtypes is infre-
quent. Of note, an exact role for EBV in eBL lymphomagenesis
has not been established yet. However, it has been proposed
that there might be a substantial difference in the pathogenetic
pathways exerted by EBV in BL-like and LCL-like B cell lym-
phomas: while the former might primarily depend upon the
anti-apoptotic effects of EBV, the driving force for the lat-
ter could be the main transforming latent protein of EBV i.e.,
EBNA-2 (Niller et al., 2004). Furthermore, molecular differ-
ences between EBV+ and EBV-negative (EBV−) BL have been
reported (Giulino-Roth et al., 2012; Onnis et al., 2012; Shi
et al., 2013). Since only one EBV latent protein (EBNA-1) is
expressed in BL, a substantial role for EBV-encoded miRNAs
in BL has been hypothesized. The expression of EBV miRNAs
differs between malignant BL primary tumors and normal B
cells from the same patients, being some BART miRNAs absent
in non-clonal B cells (Qiu et al., 2011). Furthermore, BART
miRNAs have been demonstrated to play a very important role
in maintaining the malignant phenotype of BL (Vereide et al.,
2014).
Of note, a recent study has addressed the dependency of
the malignant phenotype of PTLD and BL cell lines on EBV.
Interestingly, a higher level of dependency upon EBV was demon-
strated for PTLD cell lines, when compared to BL cell lines
(Vereide and Sugden, 2011).
In this work, we aimed at investigating the participation of
different latency programs to EBV-related lymphomas at the
molecular level. In this regard, we chose to look at EBV-positive
(EBV+) BL and EBV+ PTLD_DLBCL as two models represent-
ing latency types I and II/III, respectively (i.e., conditions in which
EBV oncoproteins are mainly involved or not), and addressed
the different contribution of EBV to the transcriptional land-
scape of these lymphomas by comparing their gene and miRNA
expression signatures.
EXPERIMENTAL PROCEDURES
ETHICS STATEMENT
The study was conduced in Italy according to the principles of
the Helsinki declaration after approval of the Internal Review
Board. Written informed consent was obtained from all patients
for tissue/cells analysis.
STUDY DESIGN
We studied a total of 29 EBV+ BL cases, and 28 EBV-positive
Post-Transplant Lymphoproliferative Disease (PTLD) morpho-
logically defined as diffuse large B-cell lymphomas (DLBCL).
Briefly, DLBCL cases presented with either early (N = 10) or late
(N = 13) onset, and EBV latency type II (N = 8) or III (N = 13)
or not defined (N = 2). Details on such cases are reported in
Supplementary Data Sheet 1.
This study was designed in three phases (Figure 1). In the
first phase, we compared the miRNA and gene expression pro-
file (GEP) of EBV+ BL and EBV+ PTLD_DLBCL, in order to
evaluate their similarities/differences. Second phase was aimed to
explore the effect of EBV on the global gene expression of the
two tumors. For this purpose, by means of Gene Set Enrichment
Analysis (GSEA), the expression of the genes deregulated by EBV
latent proteins (extracted from the literature), or the genes dereg-
ulated by one of EBV-encoded miRNAs, i.e., ebv-miR-BART6-3p
(which were determined experimentally) was evaluated in EBV+
BL and EBV+ PTLD_DLBCL. In the third phase, we looked for
the genes targeted by EBV latent proteins and miRNAs among
genes differentially regulated in the considered tumor categories
and looked for their enrichment in biological processes and path-
ways using Molecular Signature DataBase (MsigDB) web-based
tool, as describer later.
An analog approach, except for the third phase, was used to
investigate possible differences between EBV+ PTLD_DLBCLs
characterized by latency types II or III.
CELL TRANSFECTION AND MICROARRAY HYBRIDIZATION
In order to determine the ebv-miR-BART6-3p targets,
EBV-negative Akata 2A8 or EBV+ Akata cells were transiently
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FIGURE 1 | Study design. This project, with goal of comparing the role of EBV
in EBV+ BL and EBV+ PTLD_DLBCL, was designed in three phases. In the first
phase, the molecular signatures of the two tumors were compared for both
gene expression and miRNA profiling (middle panel, orange). In the second
phase, the role of viral latent proteins and EBV-encoded miRNA
ebv-miR-BART6-3p was evaluated, by usage of Gene Set Enrichment Analysis
(top panel, violet). In the third phase, the differentially expressed genes in the
two tumorswere coupled to the correspondingmiRNA, in EBV+BL, or to latent
proteins, in EBV+ PTLD_DLBCL. The extracted genes were further analyzed in
the terms of biological processes and pathways (bottom panel, yellow).
transfected with synthetic ebv-miR-BART6-3p mimic or
inhibitor (100 nM; Custom synthesized by Dharmacon- Thermo
Scientific, Germany), respectively. For each treatment, a further
transfection with corresponding negative control was performed
as well (10 nM; I-300145-01, Dharmacon- Thermo Scientific,
Germany). The transfection of 5 × 106 cells per treatment was
performed by Amaxa nucleofector apparatus (Amaxa, Cologne-
Germany), using the program G23 and the transfection solution
V according to the manufacturer’s instructions. Transfection
efficiency was assessed by means of a further treatment (2µg
of pmaxGFP) and detection of both fluorescence and cell via-
bility by flow cytometry. Twenty four hours post-transfection,
cells were harvested and RNA was extracted using Trizol, and
transfection efficiency was further confirmed by evaluating the
expression level of ebv-miR-BART6-3p using q-PCR by means
of Taqman probes, employing RNU43 as housekeeping miRNA
(Applied Biosystems, Cologne, Germany), as described (Onnis
et al., 2012). RNA was further hybridized to HuGene-2.0-st array
(Affymetrix, Santa Clara, CA) according to the manufacturer’s
instructions. The resulting data are available online at the Gene
Expression Omnibus (www.ncbi.nlm.nih.gov/projects/geo/),
accession number GSE63665.
VIRAL miRNA TARGET PREDICTION
The prediction of viral miRNAs targets was accomplished using
Viral microRNAHost Target Database (vHoT DB), which collects
the target predictions from 5 publicly available databases, includ-
ing TargetScan, miRanda, RNAhybrid, DIANA microT, and PITA
(Kim et al., 2012). The variables were set as follows: Minimum
Free Energy (MFE) threshold values for miRanda and RNAhybrid
were set to −30 and −40 kcal/mol, respectively; Total Context
Score threshold value for Targetscan was set to −1, and the Score
threshold value for DIANA microT and ddG threshold value for
PITA were set to the default. For each miRNA, the targets that
were found in at least 3 out of 5 databases were chosen.
MicroRNA EXPRESSION PROFILING ANALYSIS
MicroRNA expression profiling was performed on 17 cases of
EBV+ BL and 5 cases of EBV+ PTLD_DLBCL, for which
Formalin Fixed Paraffin Embedded (FFPE) tissues were avail-
able in the archives of the Hematopathology Unit in Bologna
and the Pathology Unit in Siena (Supplementary Data Sheet 2),
using the nCounter® miRNA Expression Assay Kits (NanoString
Technologies, Seattle, WA, USA). Raw data coming from
nCounter® miRNA Expression Assay were normalized using
NanoStringNorm package developed in R 2.15 version. Briefly,
probe levels quantified by microarrays were adjusted for miR-
NAs with specific background correction factor. Technical nor-
malization was performed using geometric mean of positive
controls and mean of negative controls for background sub-
traction. Lastly, the dataset was normalized such that the mean
of each gene is zero. The data were further analyzed in the
terms of Unsupervised Hierarchical Clustering Analysis (HCA)
and Principal Component Analysis (PCA) using GeneSpring ver-
sion (Agilent Technologies), as described (Piccaluga et al., 2007,
2008, 2011). The miRNAs differentially expressed among the two
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categories were selected on the basis of the following criteria:
fold change ≥2, corrected p-value (Benjamini-Hockeberg FDR)
≤0.05.
GENE EXPRESSION PROFILING ANALYSIS
For gene expression profiling, the CEL files of 23 cases of
EBV+ PTLD_DLBCL (Supplementary Data Sheet 1) and 12
cases of EBV+ BL were extracted from Gene Omnibus Database
(GSE38885, GSE26673; Piccaluga et al., 2011; Morscio et al.,
2013a). The CEL files were quantile normalized and log2 trans-
formed using rma method implemented by means of affy
Bioconductor R package.When comparing EBV+ PTLD_DLBCL
cases with EBV+ BLs, the resulting matrix was further nor-
malized for batch effect by means of ComBat package in R.
Furthermore, in all cases a further step of mean-variance nor-
malization was achieved using geWorkbench 2.4.1. Unsupervised
HCA was performed usingMeV 4.9 software. Because of memory
constraints of this software, the top 7 × 103 probes in the terms
of highest standard deviation were chosen. Unsupervised PCA
was done by means of R software. Supervised analysis (two-tails
student T-test) was performed to obtain molecular signatures of
different tumors using geWorkbench 2.4.1 software and filtered
using the following criteria: p-value≤0.05, fold change≥2.When
comparing EBV+ BL vs. EBV+ PTLD_DLBCL, the analysis was
also performed by filtering the resulting probes against those
characterizing the molecular signature generically discriminating
BL and DLBCL described by Hummel et al. (2006). The differen-
tially expressed probes were further used to perform supervised
HCA using MeV 4.9 software. During all the analysis steps, except
for when comparing EBV+ BL against the whole set of EBV+
PTLD_DLBCLs, the two EBV+ PTLD_DLBCL cases for which
the latency type was not available were omitted.
The CEL files resulting from ebv-miR-BART6-3p transfection
experiments were normalized and analyzed as described above,
except for ComBat normalization, which was omitted in this case.
IDENTIFICATION OF EBV TARGET GENES
To identify the possible targets of EBV, we looked for the predicted
and experimentally established targets of EBV-encoded products
in the genes differentially expressed in the two tumor categories.
For the potential target genes of latent proteins, we used the
previously published data, which addressed the effect of EBV
latent proteins on the molecular profile of the cells, as a source
of target genes. These studied latent proteins included EBNA-
1 (Dresang et al., 2009), EBNA-2 (Maier et al., 2006), EBNA-3
proteins (EBNA-3s, White et al., 2010) and LMP-1 (Vockerodt
et al., 2008). In the case of EBNA-3s, we decided to consider
the effect of their simultaneous expression, since a possible col-
laboration among them has been proposed (White et al., 2010).
Furthermore, we excluded EBNA-LP, since the only study that has
addressed its effect on the—global gene signature of human cells,
gave result to a too small number of genes to be used for GSEA
(Kanamori et al., 2004). Whenever possible, the genes with the
following criteria were chosen: p-value≤0.05, fold change≥2.We
then looked for these target genes among the genes differentially
expressed in EBV+ PTLD_DLBCL vs. EBV+ BL, taking a posi-
tive correlation approach, i.e., the genes that were up-regulated by
latent proteins were searched for in those up-regulated in EBV+
PTLD_DLBCL and vice versa.
In the case of EBV-encoded miRNAs, we took into account
both experimentally found targets (i.e., those resulting from the
ebv-miR-BART6-3p transfection experiment described in this
paper) and those predicted by at least 3 prediction algorithms
(described above). We then searched for these targets in the genes
differentially expressed in the considered tumor categories, keep-
ing a negative correlation manner, i.e., targets of up-regulated
miRNAs in a tumor were looked for in the genes down-regulated
in that tumor and vice versa.
Furthermore, the common potential target genes of either
miRNAs or viral latent proteins down-regulated in a tumor entity
and up-regulated in the other were identified.
GENE SET ENRICHMENT ANALYSIS (GSEA)
Enrichment in expression of EBV target genes was evaluated using
Gene set enrichment analysis (GSEA) software on the set samples
described above (EBV+ BL vs. EBV+ PTLD_DLBCL or EBV+
PTLD_DLBCL of latency type II vs. EBV+ PTLD_DLBCL of
latency type III).
GSEA of the genes potentially deregulated by EBV was per-
formed in the terms of Gene Ontology Biological Process and
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways by
means of GSEA MsigDB (www.broadinstitute.org/gsea/msigdb)
web-based analysis tool, using the default options (displaying top
10 gene sets with FDR q-value below 0.05).
RESULTS
EBV+ BL AND PTLD_DLBCL HAVE DIFFERENT MOLECULAR PROFILES
To unveil the possible molecular differences/similarities between
EBV+ BL and EBV+ PTLD_DLBCL, we performed a compari-
son of the expression profile of both genes and miRNAs between
the two entities. In particular, for GEP we used 12 cases of
EBV+ BL and 23 cases of EBV+ PTLD_DLBCL which were pre-
viously generated and available at GEO database. For miRNA
profiling, including both viral and cellular miRNAs, we used 17
EBV+ BL and 5 EBV+ PTLD_DLBCL cases that were profiled by
Nanostring technology.
The unsupervised analysis, i.e., unsupervised HCA and PCA,
did not allow to clearly discriminate between the two categories
on both gene (Figures 2A,B) and miRNA profiling (Figure 2C).
In order to identify possible differences between the tumors, a
supervised test was then performed. As far as GEP was concerned,
we found 780 probes significantly up-regulated in EBV+ BLs, and
1247 probes significantly up-regulated in EBV+ PTLD_DLBCLs,
which corresponded to 513 and 801 unique genes, respectively
(Supplementary Data Sheet 3).
Regarding the miRNA profiling, on the other hand, we found
36 miRNA differentially expressed: 21 of these miRNAs were
over-expressed in EBV+ BLs and most (n = 17) consisted of
EBV-encoded miRNAs. The over-expressed miRNAs in EBV+
PTLD_DLBCLs (n = 14) were almost entirely cellular miR-
NAs with the exception of one EBV-encoded miRNA, i.e., ebv-
miRBHRF-1-2 (Table 1).
Of note, following recognition of the differentially expressed
genes and miRNAs, a supervised HCA led to a clear distinction
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FIGURE 2 | Gene and miRNA expression analysis of EBV+ BL and EBV+
PTLD_DLBCL. Unsupervised analyses failed to distinguish the two tumor
entities. (A) Unsupervised hierarchical clustering based on gene expression
is depicted. (B) Principal Component Analysis showed a significant overlap of
the two tumor entities. The three main components (i.e., groups of genes)
are represented in the three axes (x, y, and z). (C) Unsupervised hierarchical
clustering based on the expression of viral and cellular miRNA was again
unable to discriminate the two entities. Together, these data indicate that
EBV+ BL and EBV+ PTLD_DLBCL present significant similarities in both their
gene and miRNA expression profiles. In the heat-map each row represents a
gene (A) or miRNA (C) and each column represents a sample. The color
scale illustrates the relative expression level of a gene across all samples: red
represents an expression level above the mean, green represents expression
lower than the mean.
between the two, for both genes (Figure 3A) and miRNAs
(Figure 3B). Interestingly, when examining differentially
expressed viral miRNAs only (excluding cellular miRNAs), it was
still possible to efficiently discriminate the two tumor entities
(Figure 3C).
EBV-ENCODED LATENT PROTEINS MIGHT SIGNIFICANTLY AFFECT THE
MOLECULAR SIGNATURE OF EBV+ PTLD_DLBCL
To investigate how the latent proteins encoded by EBV, which are
predominantly expressed in EBV+ PTLD_DLBCL rather than in
BL, might impact the molecular profile of our entities, we exam-
ined the expression of their target genes. In particular, we focused
on the genes the expression of which was regulated by EBNA-1,
EBNA-2, EBNA-3s and LMP-1, and by means of GSEA, we tested
their expression in EBV+ BL vs. EBV+ PTLD_DLBCL.
The genes induced (n = 44) or suppressed by EBNA-1 (n =
36) resulted in no significant enrichment (corrected p-value
equal to 0.384 and 0.179 for induced and suppressed genes,
respectively). Conversely, the genes induced by EBNA-2 (n = 52),
EBNA-3s (n = 810) and LMP-1 (n = 249) all turned out to be
significantly enriched in EBV+ PTLD_DLBCL, with high con-
fidence (corrected p-value equal to 0.009, 0.000, and 0.0001,
correspondingly). Accordingly, the genes whose expression was
suppressed by EBNA-2 (n = 23), EBNA-3s (n = 483) and LMP-
1 (n = 308) were all clearly enriched in EBV+ BL (corrected
p-value equal to 0.005, 0.000 and 0.018, respectively) (Figure 4).
Together, these results provide strong evidence that different
EBV latent protein expression profiles influence the transcrip-
tional programs of EBV-associated BL- and PTLD_DLBCL-cells.
Moreover, they indicate that EBV largely affects PTLD gene
expression profile mainly through viral latent protein expression,
while little of this viral latent protein activity is exerted in BL.
ebv-miR-BART6-3p, AN EBV-ENCODED miRNA, CAN INFLUENCE THE
MOLECULAR PROFILE OF EBV+ BL
In order to evaluate the impact of the differentially expressed
EBV-encoded miRNAs on the global GEP of the tumors, we then
selected a model that served as proof of principle. Specifically,
we chose ebv-miR-BART6-3p, as it turned out to be among
the top 3 viral miRNAs in the terms of the highest number
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Table 1 | Differentially expressed miRNAs in EBV+ BL and EBV+ PTLD_DLBCL.
MicroRNA P-value FC (abs) Regulation Accession
ebv-miR-BART19-3p 5.04E-005 7.3412666 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00733.1
ebv-miR-BART17-3p 5.57E-004 9.606497 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00729.1
hsa-miR-92a 6.75E-004 2.9477286 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00668.1
ebv-miR-BART22 0.00101368 14.518561 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00741.1
ebv-miR-BART8 0.00143009 5.792101 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00748.1
ebv-miR-BART3 0.00156815 8.551074 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00742.1
ebv-miR-BART9 0.001634 8.696155 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00749.1
ebv-miR-BART1-3p 0.00232697 6.0770316 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00719.1
ebv-miR-BART4 0.00274992 4.232079 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00743.1
ebv-miR-BART11-5p 0.00428005 5.031375 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00723.1
ebv-miR-BART19-5p 0.00479706 5.03283 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00734.1
hsa-miR-484 0.00649317 2.6175013 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00385.1
hsa-miR-1274b 0.00677765 2.1696913 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00093.1
kshv-miR-K12-6-5p 0.00678478 2.0836391 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00795.1
ebv-miR-BART21-3p 0.00949766 3.7267542 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00739.1
ebv-miR-BART10 0.01241677 3.8621666 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00721.1
ebv-miR-BART6-3p 0.01335738 3.816174 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00745.1
ebv-miR-BART12 0.01714046 3.8982465 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00724.1
ebv-miR-BART6-5p 0.01769217 3.296042 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00746.1
hsa-miR-20a+hsa-miR-20b 0.01775939 23.560373 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00236.1
ebv-miR-BART17-5p 0.02827049 2.9462714 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00730.1
ebv-miR-BART7 0.0311731 3.0952694 Up-regulated in EBV+ BL
(Down-regulated in EBV+ PTLD_DLBCL)
nmiR00747.1
hsa-miR-155 1.03E-006 9.04388 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00178.1
hsa-miR-630 3.43E-004 8.03204 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00586.1
hsa-miR-1978 6.99E-004 3.3640883 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00694.1
hsa-miR-211 0.00150208 4.2735744 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00240.1
hsa-miR-663b 0.00248701 3.742663 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00621.1
hsa-miR-494 0.00359945 149.04005 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00400.1
(Continued)
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Table 1 | Continued
MicroRNA P-value FC (abs) Regulation Accession
hsa-miR-1973 0.00667112 2.7127783 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00689.1
hsa-miR-21 0.01024776 2.768076 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00238.1
hsa-miR-24 0.01031194 2.183924 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00261.1
hsa-miR-1308 0.01368784 3.4283412 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00131.2
hsa-miR-222 0.01613653 2.0202823 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00256.1
hsv1-miR-H8 0.03170305 2.972884 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00779.1
ebv-miR-BHRF1-2 0.03283407 3.6006873 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00751.1
hsa-miR-330-5p 0.03623376 2.563781 Up-regulated in EBV+ PTLD_DLBCL
(Down-regulated in EBV+ BL)
nmiR00307.1
FIGURE 3 | EBV+ BL and EBV+ PTLD_DLBCL have different molecular
profiles. Supervised analysis identified genes and miRNAs differentially
expressed in EBV+ BL vs. EBV+ PTLD_DLBCL. (A) Supervised hierarchical
clustering based on the differentially expressed genes is shown. (B)
Supervised hierarchical clustering based on the differentially expressed
miRNAs, including both viral and cellular miRNAs is shown. (C) Supervised
hierarchical clustering based on the differentially expressed viral only
miRNAs is presented. In the heat-map each row represents a gene (A) or
miRNA (B,C) and each column represents a sample. The color scale
illustrates the relative expression level of a gene across all samples: red
represents an expression level above the mean, green represents
expression lower than the mean.
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of target genes predicted by conventional bioinformatics tools
(Supplementary Data Sheet 4) and its predicted effects could be
biologically sound. We then transfected Akata 2A8 (EBV−) and
Akata (EBV+) cells by either mimic or inhibitor of ebv-miR-
BART6-3p, respectively, and generated gene expression profiles
FIGURE 4 | Gene Set Enrichment Analysis (GSEA) of EBV latent
proteins-dependent signatures reveals their effect on the molecular
profiles of EBV+ PTLD_DLBCL. The effect of viral latent proteins
expressed across the different latency programs were investigated in EBV+
PTLD_DLBCL and EBV+ BL. GSEA was applied to study the expression of
target genes of the latent proteins of EBV in the two tumor types. For each
latent protein (EBNA-1, EBNA-2, EBNA-3s, and LMP-1) induced or
suppressed targets were analyzed (left and right, respectively). While
EBNA-1 targets were not significantly affected, as expected by the latency
program, EBNA-2, EBNA-3s, and LMP-1 targets appeared to be significantly
enriched in either one group. Particularly, induced targets were enriched in
EBV+ PTLD_DLBCL and the suppressed ones were enriched in EBV+ BL.
of the treated cells. Ectopic expression of ebv-miR-BART6-3p
led to induction of 593 and suppression of 724 probes, while in
the case of knocking down this miRNA, we found 861 probes
under-expressed and 1074 probes over-expressed (Supplementary
Data Sheet 5, 6). Totally, we detected 962 and 746 unique genes
to have either positive or negative correlation with ebv-miR-
BART6-3p expression, respectively (Supplementary Data Sheet
7). Interestingly, when examined using GSEA, genes with negative
correlation with ebv-miR-BART6-3p were significantly enriched
in EBV+ PTLD_DLBCLs (p = 0.040), while those with a pos-
itive correlation were significantly enriched in EBV+ BLs (p =
0.006, Figure 5). This result proved that BL and PTLD differen-
tially modulate in vivo (i.e., in primary tumors) genes targeted by
differentially expressed viral miRNAs (e.g., ebv-miR-BART6-3p)
and indicated that miRNA expression is the primary mechanism
through which EBV does influence the molecular profile of BL
cells.
EBV-DEREGULATED GENES IN DIFFERENT EBV LATENCY TYPES MIGHT
INTERFERE WITH RELEVANT BIOLOGICAL ACTIVITIES
As it appeared that EBV significantly affected, though in dif-
ferent ways, the global GEP of both BL and PTLD-DLBCL, we
investigated whether genes likely to be modulated by EBV were
involved in specific biological functions, aiming to further appre-
ciate its specific role in the pathobiology of these lymphomas. In
particular, we evaluated the genes regulated by EBNA-2, EBNA-
3s, LMP-1, the ones predicted to be targets of the EBV-encoded
miRNAs as well as those induced and suppressed by ebv-miR-
BART6. In addition, we looked for EBV target genes that might be
induced in one tumor group and suppressed in the other group
by different mechanisms.
FIGURE 5 | ebv-miR-BART6-3p expression can affect the molecular
profile of EBV+ BL. Based on the number and biological importance of its
predicted target genes, ebv-BART6-3p was chosen as a proof of principle
for investigating the potential effect of viral miRNAs in EBV+ BL. Akata 2A8
(EBV−) and Akata (EBV+) cells were transfected with ebv-BART6-3p mimic
or inhibitor, respectively, along with the corresponding controls, and gene
expression analysis was performed by Affymetrix HuGene 2.0 microarray.
Genes up-regulated upon ebv-BART6-3p inhibition and down-regulated
upon ebv-BART6-3p induction were significantly enriched in EBV+
PTLD_DLBCL cases (left panel). Conversely, genes down-regulated upon
ebv-BART6-3p inhibition and up-regulated upon ebv-BART6-3p induction
were significantly enriched in BL (right panel). Both results were then
consistent with ebv-BART6-3p expression and active role in BL.
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Specifically, 174 (21.7%) of the genes up-regulated and 61
(11.8%) of the genes down-regulated in EBV+ PTLD_DLBCL
vs. EBV+ BL were found to be potentially induced or sup-
pressed by latent proteins, respectively (Supplementary Figures
1A and 1B, Supplementary Data Sheet 8, 9). On the other
hand, 113 (14%) of the genes down-regulated and 21 (4%)
of the genes up-regulated in EBV+ BL were found likely to
be regulated by differentially expressed BART miRNAs (includ-
ing ebv-miR-BART6-3p) or ebv-miR-BART6-3p, accordingly
(Supplementary Figures 1C,D, Supplementary Data Sheet 10,
11). Furthermore, we identified 38 common target genes that
could potentially be repressed by EBV miRNAs in EBV+
BL, or conversely, be induced by latent proteins in EBV+
PTLD_DLBCL (Supplementary Figure 1E, Supplementary Data
Sheet 12).
The potential role of such modulated genes was investigated
looking at their enrichment in GO biological processes and
KEGG pathways. It was found that the genes purportedly up-
regulated by EBV latent proteins in EBV+ PTLD_DLBCL were
significantly enriched in functions such as apoptosis, immune
response and developmental regulation (Supplementary Figure
2A), while the genes down-regulated by latent proteins in this
tumor were enriched in processes especially related to RNA
metabolism, including transcription, regulation of gene expres-
sion, and RNA biosynthesis-related processes (Supplementary
Figure 2B). On the other hand, the genes possibly suppressed by
EBV-encoded miRNAs in EBV+ BL were significantly enriched
in regulation of different biological processes like signal trans-
duction, gene expression and metabolism (Supplementary Figure
2C). Furthermore, possible common target genes of EBV sup-
pressed in EBV+ BL and induced EBV+ PTLD were significantly
enriched in regulation of apoptosis, immune system process,
humoral immune response, and regulation of different biological
processes (signal transduction, gene expression and metabolism),
(Supplementary Figure 2D). The ebv-miR-BART6-3p targets
induced in EBV+ BL were not meaningfully enriched in any GO
processes.
Concerning the enrichment of our gene sets in KEGG path-
ways, for the potential targets of latent proteins of the virus up-
regulated in EBV+ PTLD_DLBCL the enrichment was notably
observed for JAK-STAT, small cell lung and pancreatic-related,
chemokine, cytokine-cytokine receptor, Toll like receptor, and
apoptosis signaling pathways (Supplementary Figure 2E). On
the other hand, potential targets of viral miRNAs suppressed
in EBV+ BL were enriched, most remarkably, in cytokine and
chemokine-related, JAK-STAT and small cell lung cancer signal-
ing pathways (Supplementary Figure 2F). In addition, probable
common target genes of EBV that were suppressed in EBV+
BL and induced in EBV+ PTLD were enriched in chemokine
and cytokine, apoptosis and cancer related (small cell lung can-
cer, pancreatic and prostatic cancers) pathways (Supplementary
Figure 2G). No pathway enrichment was found for EBV target
genes down-regulated in EBV+ PTLD_DLBCL and up-regulated
in EBV+ BL.
Together, these data suggest that EBV modulation of the tran-
scriptional profile of BL and PTLD acts through the differential
regulation of relevant cellular programs that are consistent with
the status of the host immune system in which lymphomagenesis
occurs.
PTLD_DLBCLs ARE SLIGHTLY DIFFERENT BASED ON THE EBV LATENCY
PROGRAM
In this study we aimed to investigate the main differences between
EBV-associated lymphomas characterized by different expression
of EBV-encoded molecules (i.e., diverse latency patterns). To
this aim, we used EBV+ BL as prototypic example of latency
type I and EBV+ PTLD_DLBCL as example of latency types
II/III. As differences emerged between the two diseases appar-
ently related to the differential expression of miRNAs, EBNAs and
LMP-1 when PTLD_DLBCL were considered as unique group
(the majority of cases displaying a latency type III pattern), we
intended to verify the real homogeneity of this tumor.
When studied by unsupervised analysis, all EBV+
PTLD_DLBCLs were mixed up, irrespectively of the latency
type (Supplementary Figure 3A). Conversely, when a supervised
approach was adopted, we identified 974 probes (equivalent
to 623 genes) differentially expressed in EBV+ PTLD_DLBCL
latency type II vs. EBV+ PTLD_DLBCL latency type III
(Supplementary Data Sheet 13; Supplementary Figure 3B). Based
on that, we specifically studied by GSEA the possible contribution
of EBV-encoded molecules. As expected, in line with previous
results, the two groups showed differences only related to EBNA-2
and EBNA-3s expression; particularly, genes up-regulated upon
EBNA-2/EBNA-3s induction were up-regulated in latency type III
PTLD_DLBCLs (Supplementary Figure 4). By contrast, no sig-
nificant differences emerged when EBNA-1, LMP-1, and miRNA
related signatures were tested (Supplementary Figures 4, 5).
Finally, in order to challenge the robustness of our results
on EBV+ BL (that rely on the comparison with EBV+
PTLD_DLBCL as a unique group) we tested how homogeneous
is EBV+ PTLD_DLBCL in comparison to EBV+ BL regard-
ing the EBV signatures. Indeed, by hierarchical clustering we
observed that all EBV+ PTLD_DLBCLs, except one case, irre-
spective of the latency type clustered together in one branch, while
EBV+ BL clustered in the other branch, with only one exception
(Supplementary Figure 6A). Consistently, when only EBV-driven
genes differentially expressed between EBV+ BL and EBV+
PTLD_DLBCL latency type III were considered (Supplementary
Data Sheet 14), EBV+ PTLD_DLBCL latency type II clearly clus-
tered within EBV+ PTLD_DLBCLs, being well distinct from
EBV+ BL (Supplementary Figure 6B).
Together, these data indicate that, despite some differences
mainly related to EBNAs, EBV+ PTLD_DLBCL, independently
from latency type, represents a relatively homogeneous group of
tumors that can be reliably used as a model against EBV+ BL.
DISCUSSION
Numerous studies suggest how, by means of its limited but well-
evolved “arsenals,” EBV might disrupt and/or recruit physiologic
mechanisms of the cell and affect different aspects of cell’s life,
which might result to its contribution to different malignan-
cies (Thorley-Lawson, 2001; Dirmeier et al., 2003; Altmann and
Hammerschmidt, 2005; Barth et al., 2008; Allday, 2009; Babu
et al., 2011; Onnis et al., 2012). These arsenals include a set of
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9 latent proteins, two non-encoding RNA molecules (EBERs),
and a set of miRNAs, belonging to two families called BART and
BHRF.However, in different conditions, the virus expresses differ-
ent combinations of these molecules, which are defined as latency
types (De Falco et al., 2009; Camargo et al., 2011; Grinde, 2013;
Grywalska et al., 2013).
Latency type I is primarily observed in BL, where only one
latent protein (EBNA-1), EBERs and BART microRNAs are
expressed (Bellan et al., 2005; Piccaluga et al., 2011; Qiu et al.,
2011). On the other hand, the most extreme expression pattern,
called latency type III, which includes the expression of all latent
proteins, EBERs and, both BART and BHRFmiRNAs, is observed
in lymphoblastoid cell lines, and a fraction of PTLDs in immuno-
suppressed individuals (Xia et al., 2008; Morscio et al., 2013a,b).
The other type of EBV latency, i.e., type II, which is characterized
by the expression of most of EBV latent proteins and BART miR-
NAs, plus a faint expression of BHRFmiRNAs. This latency type is
found in a fraction of PTLDs, Hodgkin’s Disease Nasopharyngeal
Carcinoma and Gastric Carcinoma (De Falco et al., 2009; Qiu
et al., 2011).
Although the role of EBV in BL has been debated at some
times, several documents indicate the possibility of such a role.
The most striking in vitro evidence of such role is based on nat-
ural selection: despite the possibility of the harboring cells to
lose EBV by chance, infected tumor cells sustain it, indicating
their dependency upon the virus (Vereide and Sugden, 2009).
The model proposed by Niller and Minarovits was the first to
make the clear distinction between transformation being the driv-
ing force of LCL-like tumors, while anti-apoptosis being the key
mechanism for BL-like tumors (Niller et al., 2003, 2004, 2014).
Concordantly, it’s been recently revealed that BL cells need to
maintain the EBV genome, at least to inhibit apoptosis (Vereide
et al., 2014). Furthermore, a recent study that sequenced a lim-
ited set of genes in primary BL samples found fewer mutations in
EBV+ BLs, when compared with EBV- BLs, which could reflect
how these mutations might compensate for the anti-apoptotic
functions of EBV in some cases of EBV-negative sporadic BL.
(Giulino-Roth et al., 2012). Of note, a study performed in Uganda
uncovered that antibody titers against EBV are higher in children
that will develop BL (De-The et al., 1978).
On the other hand, the substantial participation of EBV in
EBV+ PTLD is more accepted: immunosuppressed patients with
lower cytotoxic T cell response have a higher rate of circulating
EBV and restoration of T cell immune response is a major strategy
in treating PTLD (Savoldo et al., 2006; Bollard et al., 2012). EBV+
PTLD cell lines are more sensitive to inhibitors of PI3K/mTOR
and HSP90 than EBV-negative lymphoma (Alsayed et al., 2008).
Furthermore, EBV might interfere with apoptotic pathways: in
EBV+ PTLD, the expression level of proapoptotic protein Bim, a
critical regulator of lymphocyte survival, is lower when compared
to EBV- PTLDs (Ghigna et al., 2013). In addition, the forced loss
of EBV in EBV+ PTLD cell lines might result in death, induced
by apoptosis (Vereide and Sugden, 2011).
In the recent years, an increasing usage of high through-
put technologies like microarray profiling, and more recently
next generation sequencing, has been applied to address the
role of EBV in different EBV-related malignancies achieved by
comparing the same categories of tumors or tumor-driven cell
lines harboring or lacking the virus, or confronting different EBV-
related tumors at both levels of gene and miRNA profile (Lenze
et al., 2011; Piccaluga et al., 2011; Qiu et al., 2011; Yang et al.,
2013). However, to our knowledge, no research has ever dealt with
a comparison of EBV+ BL in primary tumors, neither at the level
of GEP, nor at the level of miRNA profiling.
In this work, we compared the gene and miRNA expres-
sion profiles of EBV+ BL and EBV+ PTLD_DLBCL (the
most common subtype of PTLD), aiming to reveal their dif-
ferences/similarities and exploring how the observed similari-
ties/differences could be related to different EBV latency types,
which is of type I and types II/III for the former and latter, respec-
tively. We observed that the two entities might be distinguished by
a differentiating molecular signature, and, more importantly, we
showed that the EBV-encoded latent proteins and miRNAs can
affect the molecular signature of the two tumors. Furthermore,
we found that the genes affected by viral products in the two
tumors might reflect how the virus might use different/similar
and sometimes conflicting strategies when the latency type relies
mainly on miRNAs (i.e., type I) or genes/proteins (i.e., types
II-III).
When we compared the gene expression profiles, unsuper-
vised analysis could roughly distinguish the two entities, although
a supervised clustering could clearly make such discrimination.
Further, as this is the first report comparing EBV+ BL and EBV+
PTLD_DLBCL, in order to exclude the influence of genes dif-
ferentially expressed due to the origin of the two tumors (i.e.,
BL vs. DLBCL) we also performed the same analysis by filtering
the results against the molecular signature of BL (5, 22). Indeed,
the same pattern of clustering was observed (Figure 2) (Hummel
et al., 2006; Piccaluga et al., 2011).
Similar to GEP, miRNA profiling was far more discriminating
in supervised rather than the unsupervised analysis. Interestingly,
the major part of differentially expressed miRNAs belonged to
those encoded by EBV. In addition, we found a lowered expression
of BART cluster miRNAs in EBV+ PTLD_DLBCL, while only one
BHRF-1-derived miRNA was found to be induced in this tumor.
Furthermore, we observed a higher expression of several cellu-
lar miRNAs in EBV+ PTLD_DLBCL, among which well-known
oncomiRNA mir-155 was notable.
The lower expression of BART miRNAs in EBV+ PTLD
in comparison with EBV+ BL in primary tumors has not
been reported by now. Although Qiu et al. reported a down-
regulation of BART cluster miRNAs in LCL, when compared to
Nasopharyngeal Carcinoma and Gastric Carcinoma (which dis-
play latency type II), contrary to our results, they identified a
matched pattern of BART miRNAs expression in BL biopsies and
LCLs (Qiu et al., 2011). It must be noted, though, that LCLsmight
not be a good representative for EBV+ PTLD_DLBCL tumor
samples in every aspect of them. Interestingly, when, by means
of GSEA software, we applied our set of genes deregulated by
ebv-miR-BART6-3p to EBV+ PTLD_DLBCL of latency type II
vs. EBV+ PTLD_DLBCL of latency type III, we found no signifi-
cant enrichment in any of the two categories, which might either
indicate a similar expression level of at least ebv-miR-BART6-3p
(or maybe other EBV-encoded miRNAs), or compensation of the
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related effects by other virus-encoded products, like EBNA-2, or
by differences, e.g., genetic/epigenetic events, in the host cells.
It’s generally suggested that BHRF miRNAs are expressed
mostly in latency type III (Xia et al., 2008; Pratt et al., 2009; Qiu
et al., 2011). However, to our knowledge, the only publication that
has addressed the matter in EBV+ PTLD detected the presence
of only one single BHRF miRNA, i.e., BHRF-1-2 (Nourse et al.,
2012). It must be noted, however, that both the current and the
abovementioned analyses used FFPE tissues, and this might have
contributed to degradation of other BHRFmiRNAs, although this
needs to be further verified by miRNA profiling of paired fresh
and FFPE samples.
Furthermore, we found that in the absence of cellular miR-
NAs, viral miRNAs could distinguish the two malignancies in a
supervisedHCA, which could demonstrate a specific viral miRNA
signature for different EBV-related tumors/latency types, as sug-
gested by others (Cai et al., 2006; Pratt et al., 2009; Qiu et al.,
2011).
The higher expression of cellular miRNAs in EBV+
PTLD_DLBCL could be explained in two ways, first, it’s
well accepted that EBV latent proteins might manipulate the
expression of cellular miRNAs, as shown in the case of induction
of mir-155 by the virus and its lack of expression in primary BL
cases (Kluiver et al., 2006; Gatto et al., 2008; Linnstaedt et al.,
2010). Second, it’s been reported that BART miRNAs might
target DICER, a central component of miRNA processing, which
probably is a strategy used by the virus to counteract the cell’s
defense mechanism achieved by anti-viral miRNAs (Iizasa et al.,
2010; Skalsky et al., 2012).
It’s been known that latent proteins of EBV are able disrupt the
cellular gene expression profile, which could be achieved by direct
binding to the cell’s DNA, as in the case of EBNA-1, or by interac-
tion with different cellular proteins, which seems to be a common
phenomenon seen in all EBV latent proteins (Maier et al., 2006;
Dresang et al., 2009; White et al., 2010). For example, LMP-1, a
homolog of CD40 molecule, is able to activate important signal-
ing pathways related to growth and survival, like JAK-STAT and
NF-kB, and thus is considered an oncogene (Chen et al., 2001;
Chung et al., 2013); EBNA-1 and EBNA-3C, and the LMP-1 are
able to induce genomic instability in different manners (Gruhne
et al., 2009); and EBNA-2 interacts with Nur77 to protect against
Nur77-mediated apoptosis (Lee et al., 2004).
By means of GSEA, we were able to show how the expres-
sion of the genes deregulated by different EBV latent proteins
including EBNA-2, EBNA-3s and LMP-1 could be affected in
EBV+ PTLD_DLBCL. This is of major interest, since it success-
fully translates the obtained results of in vitro studies in an in vivo
context, and, more importantly, confirms the manipulation of
the molecular state of the tumor cells by EBV. Furthermore, lack
of this significant enrichment of EBNA-1 target genes in the
two groups might reflect how it might contribute equally to the
molecular profile of these tumors. It must be mentioned that
we excluded this type of analysis for LMP-2A and -2B, since it
has been suggested that LMP-2B regulates the activity of LMP-
2A (Rovedo and Longnecker, 2007), but no study so far has
addressed the effect of their concomitant expression on the cell’s
gene expression profile.
Recent publications point at some important roles of BART
miRNAs in the pathologic effects exerted by EBV which mostly
relate to their anti-apoptotic role in EBV-related tumors (Choy
et al., 2008; Dolken et al., 2010; Choi et al., 2013). Particularly,
Vereide et al. suggested that BL cell lines depend on BART miR-
NAs to sustain their malignant characteristics (Vereide et al.,
2014). As being concerned with the role of EBV-encoded prod-
ucts, we showed how an EBV-encoded miRNA, i.e., ebv-miR-
BART6-3p, could affect the global gene expression signature of
EBV+ BL. Aiming this as a proof of principle, it could be deduced
that other viral miRNAs might have a similar impact (Ambrosio
et al., 2014). It must be noted, however, that the final outcome
might not necessarily be simply a sum of the effect of every single
miRNA, since it has been proposed that the diseases affected by
miRNAs might be a subject of miRNA-miRNA synergism (Riley
et al., 2012).
So far, our results indicated that the EBV can change the
molecular profile of the tumors, primarily by means of its miR-
NAs and latent proteins in EBV+ BL and EBV+ PTLD_DLBCL,
respectively. We asked, however, for what reason the virus sup-
presses its BARTmiRNAs and expresses BHRF cluster in the latter,
where all the latent proteins are expressed. We deduced that it
might be explained in two ways: first, by the differences in the
strategies that the virus uses when it alternates between different
latency types, as suggested by Vereide et al. (Vereide and Sugden,
2011), and second, by the fact that in some cases there might be
a conflict between miRNAs and latent proteins, or between their
physiological effects. For example, the expression of viral latent
proteins LMP-1, LMP-2A, and EBNA-2 might be regulated by
BART miRNAs, which seems to be a strategy of the virus for con-
trolling its latency programs (Lung et al., 2009; Iizasa et al., 2010,
2012; Riley et al., 2012). In order to test this hypothesis, we tried
to determine which genes were specifically deregulated by EBV-
encoded products, and what the role of such deregulated genes
could be.
When we analyzed the genes potentially regulated by EBV
in EBV+ BL or EBV+ PTLD, by either BART miRNAs or
latent proteins, they were enriched for different biological pro-
cesses, which included regulation of apoptosis, gene expression,
immune system, and other processes. This finding supported
our first hypothesis regarding differences in the mechanisms
used by EBV in different latency types. Of note, however, KEGG
pathway analysis resulted in enrichment for both different (like
Toll Like Receptor) and common (like JAK-STAT) cancer-related
pathways.
Of note, the enrichment for cancer-related processes and path-
ways was higher in genes affected in EBV+ PTLD_DLBCL rather
than EBV+ BL. This confirms the previous findings of Vereide
et al. which discovered higher dependency for EBV in EBV+
PTLD cells, when compared to BL cells (Vereide and Sugden,
2011).
Inspired by the latter results, we asked if there were any com-
mon genes between those potentially suppressed in EBV+ BL and
those likely induced in EBV+ PTLD_DLBCL that would support
our second hypothesis. Interestingly, we found 38 genes with such
characteristics that were enriched for cancer-related processes and
pathways.
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This finding, as we suggest, gives another explanation
for which EBV turns down its BART miRNAs in EBV+
PTLD_DLBCL, where the entire set of latent proteins is expressed:
there might be a conflict between some BARTmiRNAs and latent
proteins in the modes that they influence the cellular processes,
i.e., some of the target genes that are suppressed by viral miR-
NAs might be induced by viral latent proteins. Furthermore, as
mentioned above, there might be a similar contradiction in the
way the virus might affect cellular miRNAs. Thus, simultaneous
expression of these two different categories of products might
cost the virus loss of control on its latency state, or in extreme
conditions, its ability to successfully infect the cells and produce
virions.
Collectively, our results suggest that in different malignan-
cies harboring different latency types of EBV, this virus might
exert a role by means of different and maybe conflicting mech-
anisms, which could explain differential expression of its latent
proteins and miRNAs. However, these results need to be fur-
ther confirmed by functional analysis experiments. Furthermore,
our current understanding of the role of EBV in human tumors
is mostly based on in vitro experiments. In this regard, analy-
sis of EBV-related primary tumors by means of massive parallel
sequencing methods might help us to improve our knowledge of
the manifestation of the virus in vivo and probably might result
in specific EBV-targeting therapies.
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